Bavencio

May 31, 2024

The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...

Jan 07, 2020

A South Korean startup therapeutics company Nunaps has successfully raised USD 4.2 Million around 5 billion won in a Series A round.  The investment was made by the K Partners, KTB Network, and K2 Investment Partners. Nunaps is digital therapeutics and is planning to use the funds to build its digital thera...